GILD vs NVO

Gilead Sciences and Novo Nordisk A/S, both Healthcare

Novo Nordisk A/S is the larger company at $191B against $154B. Over the past year GILD returned +38% against +1.5% for NVO.

Gilead Sciences and Novo Nordisk A/Scompared on valuation, return and Ryufin’s Smart Score
FigureGILDNVO
Last close$148$47.19
Market cap$154B$191B
Dividend yield2.1%n/a
1-year return+38%+1.5%
5-year return+160%+13%
Ryufin Smart Scoresector-relative, 1–109/109/10

Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.

Gilead Sciences

Revenue of $7.8B in Q2 2026, net income null. Its largest reported line is HIV Product Sales, 55% of the disclosed total.

GILD overviewrevenue and segmentsvaluation

Novo Nordisk A/S

NVO overviewrevenue and segmentsvaluation

Open these two in the interactive comparison to add more names, change the period or read the correlation.